Board of Directors
Dr. Graeme Wald
Principal, Healthcare Investments, One Ventures
Graeme has spent close to 25 years in financial markets as an equities analyst, fund manager and venture capitalist. He headed the Life Science research team at Wilson HTM and played a leading role in numerous IPOS’s and secondary raisings worth more than $750M. Whilst at Wilson HTM, as head of Life Science Research, Graeme was rated top analyst in the pharmaceutical sector as measured by Starmine against recommendations and investor returns. As non-executive director of Nexvet Biopharma he was chairman of the Audit and Risk committee and assisted in guiding the company to a NASDAQ listing. Whilst at Merill Lynch in South Africa, where Graeme originally hails from, he was rated top analyst in the Pharmaceutical and Healthcare sector. He was also a member of the top-rated Global Paper and Pulp Research team. Graeme has a broad range of sector experience including Life Sciences, pharmaceuticals, health care, transport, and paper and pulp. He also has experience in setting general industrial investment strategies.
Graeme has worked in Israel, America and South Africa as a research chemist in the industrial and energy sectors. He holds a PhD in chemistry and an MBA from the University of the Witwatersrand.
Dr. Tracey Brown
Independent Board Director
Tracey has over 20 years of international experience in the pharmaceutical and biotechnology industries where she has held executive roles in management of research and development programs. Tracey has built, managed and lead international product development teams which have taken products from conception through to registration. Through this process, Tracey has developed extensive experience in the identification and evaluation of suitable commercialization assets, manufacture of chemical and biological therapeutics, development and implementation of preclinical and clinical development plans, clinical program management, regulatory affairs, interaction with international regulatory agencies and product reimbursement processes. Prior to her current position as the Chief Development Officer of Anatara Lifesciences, Tracey was a co-founder of the ASX-listed company, Meditech; the Chief Scientific Officer of Alchemia and has acted as a director on the board of both listed and private biotechnology companies. Tracey also holds an adjunct Associate Professorship at Monash University where she participates in the commercialization of research and the mentoring of academic researchers to assist in their transition into the biotechnology industry. Tracey is a member of the Australian Institute of Company Directors.
Kelly is a senior business executive with 20 years of life science experience, including eight (8) recent years leading the commercialization of breakthrough digital/mobile applications in the healthcare arena. She has a proven track record driving innovation within a top global biotech organization, including formation of two intrapreneurial digital startups. Kelly has a demonstrated ability to “own” the full concept-to-launch development process for digital solutions to empower healthcare stakeholders, improve patient outcomes, increase market access, and reduce bottom-line healthcare delivery costs. Her demonstrated areas of expertise include digital & mobile health (MHealth) platforms, precision medicine, predictive modelling, point-of-care systems, EMR & HER applications, patient ID algorithms, medication adherence, health data governance, outcomes-based medicine, remote patient management, stakeholder dynamics, 3rd party collaboration, business model design, product development & fundraising, and team leadership.
Shari is Senior Business Development Manager at Murdoch Children’s Research Institute, where she where she oversees the Biotech/Medtech portfolio for the Institute; the largest child health research institute in Australia and one of the top 3 worldwide. Shari has over twenty years of experience in academic technology transfer, research contracts and intellectual property, as well as industry experience in vaccine development and drug delivery technologies. Shari holds a PhD from the University of Melbourne, an MBA from Edinburgh Business School, and is a Graduate of the Australian Institute of Company Directors .